Radiopharm Theranostics RADX
NASDAQ RADX
$1.42 -0.06 (-4.05%)
At close: Oct 2, 2026 · 4:00 PM EDT

Radiopharm Theranostics (RADX) Cash & Equivalents (2023 - 2026)

Updated

Radiopharm Theranostics (RADX) reported Cash & Equivalents of $29,354 for fiscal Q4 2026 (quarter ended Jun 30, 2026), down 84.3% from $186,474 a year earlier.

Analysis

Radiopharm Theranostics (RADX) Cash & Equivalents (2023 - 2026) Analysis & Trends

At the end of FY2026 (ended Jun 30, 2026), Radiopharm Theranostics posted Cash & Equivalents of $28,104, down 99.9% from FY2025.

  • Cash & Equivalents has a three-year compound annual growth rate of -86.6% (FY2023 to FY2026).
  • By fiscal year, Cash & Equivalents came in at $29.12 million in FY2025 (+56.8%), $18.58 million in FY2024 (+58.8%) and $11.7 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 20.42 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 6.57 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn 6.85 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 4.89 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn 3.18 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 976.00 Mn
10 Radiopharm Theranostics 5.25 Bn 5.21 Bn 186,835.86 29,353.57
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 29,353.57
Jun 30, 2025 186,473.88
Dec 31, 2024 36.44 Mn
Jun 30, 2024 122,414.06
Jun 30, 2023 11.70 Mn
API Access

Radiopharm Theranostics Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=RADX&period=max&api_key=YOUR_API_KEY